{"id":"dfd-29","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1231018","moleculeType":"Small molecule","molecularWeight":"332.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DFD-29 is being developed by Journey Medical Corporation as a novel topical treatment for bacterial skin infections. The drug is formulated to provide enhanced antimicrobial activity against common skin pathogens. It is currently in Phase 3 clinical development for dermatological indications.","oneSentence":"DFD-29 is a topical antimicrobial agent designed to treat bacterial skin infections by disrupting bacterial cell function.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:20.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial skin infections (Phase 3)"}]},"trialDetails":[{"nctId":"NCT05343455","phase":"PHASE3","title":"A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)","status":"COMPLETED","sponsor":"Journey Medical Corporation","startDate":"2022-03-29","conditions":"Papulopustular Rosacea","enrollment":330},{"nctId":"NCT05296629","phase":"PHASE3","title":"A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.","status":"COMPLETED","sponsor":"Journey Medical Corporation","startDate":"2022-03-14","conditions":"Papulopustular Rosacea","enrollment":323},{"nctId":"NCT05597462","phase":"PHASE1","title":"Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks","status":"COMPLETED","sponsor":"Journey Medical Corporation","startDate":"2022-09-30","conditions":"Rosacea","enrollment":60},{"nctId":"NCT05452785","phase":"PHASE1","title":"A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects","status":"COMPLETED","sponsor":"Journey Medical Corporation","startDate":"2022-05-07","conditions":"Pharmacokinetics","enrollment":24},{"nctId":"NCT03340961","phase":"PHASE2","title":"A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-10-01","conditions":"Rosacea","enrollment":205}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DFD-29","genericName":"DFD-29","companyName":"Journey Medical Corporation","companyId":"journey-medical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DFD-29 is a topical antimicrobial agent designed to treat bacterial skin infections by disrupting bacterial cell function. Used for Bacterial skin infections (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}